Unique roles of tryptophanyl-tRNA synthetase in immune control and its therapeutic implications

Mirim Jin1,2

Abstract

Tryptophanyl tRNA synthetase (WRS) is an essential enzyme as it catalyzes the ligation of tryptophan to its cognate tRNA during translation. Interestingly, mammalian WRS has evolved to acquire domains or motifs for novel functions beyond protein synthesis; WRS can also further expand its functions via alternative splicing and proteolytic cleavage. WRS is localized not only to the nucleus but also to the extracellular space, playing a key role in innate immunity, angiogenesis, and IFN-γ signaling. In addition, the expression of WRS varies significantly in different tissues and pathological states, implying that it plays unique roles in physiological homeostasis and immune defense. This review addresses the current knowledge regarding the evolution, structural features, and context-dependent functions of WRS, particularly focusing on its roles in immune regulation.

Introduction

Aminoacyl-tRNA synthetases (ARSs) are essential housekeeping enzymes that participate in the translation of mRNAs1. ARSs are thought to have emerged at the time of the last universal common ancestor and are distributed across all taxa2. The common aminoacylation reaction, which attaches an amino acid to its cognate tRNA, is conserved and proceeds in two steps. First, an amino acid and adenosine triphosphate (ATP), as an energy source, bind the active site of the enzyme and form an aminoacyl adenylate intermediate (amino acid-AMP); second, the adenosine monophosphate (AMP) is displaced by its cognate tRNA, resulting in the covalent linkage of the specific amino acid to one of the ribose 3′-OH moieties of a set of tRNA isoacceptors3–7. The 20 ARSs (1 for each of the 20 amino acids) are naturally categorized into two classes (I and II) based on the structure of the ancestral catalytic core, chemical properties, and consensus sequences8. Most Class I ARSs (except the Ic subclass) are monomeric, while Class II ARSs are multimeric9. Each class can be further divided into subclasses based on their unique organization of conserved structural motifs, anticodon-binding domain characteristics, and mechanical properties. The catalytic domain of all Class I ARSs has a Rossmann Fold (RF) containing the dinucleotide-binding domain; this domain carries out the aminoacylation reaction and is located at or near the N-terminus. Classically, this domain features a five-stranded parallel β-sheet connected by α-helices. Three subclasses within Class I are designated as follows: Ia, for hydrophobic amino acids (Ile, Leu, and Val), sulfur-containing amino acids (Met and Cys), and Arg; Ib, for charged amino acids (Glu and Lys) and Gln; and Ic, for aromatic amino acids, including tyrosine and tryptophan. Class II is characterized by a seven-stranded β-sheet with flanking α-helices, and it is also divided into subclasses: Class IIa, which recognizes groups with chemically similar side chains, including aliphatic (Ala and Pro) and polar (Ser, Thr, Pro, and His) amino acids and Gly; class IIb, which recognizes the charged side chains of Asp and Lys.
and Asn; and class IIC, which recognizes the aromatic amino acid Phe.\textsuperscript{4,9,10}

Interestingly, if the evolutionary tree is followed from lower to higher eukaryotes, ARSs can be seen to have progressively and irreversibly added new domains or motifs that have no apparent connection with aminoacylation.\textsuperscript{11} Five domains have been found, including the N-terminal amphiphilic helix (N-helix), the glutathione S-transferase (GST)-like domain, a helix-turn-helix motif referred to as a WHEP domain (the name is derived from four of the five WHEP-containing proteins: WRS, histidyl (H) tRNA synthetase, glutamyl-prolyl (EP)-tRNA synthetase, and methionyl tRNA synthetase), an endothelial monocyte-activating polypeptide II (EMAPII) domain, and a leucine zipper domain.\textsuperscript{4,11–15} These domains are shared by more than one ARS. By contrast, eight unique sequence motifs, referred to as UNEs, are specific to only one ARS. The UNEs from cysteinyl tRNA synthetase (CRS), glutaminyl tRNA synthetase (QRS), phenylalanine tRNA synthetase (PRS), aspartidyl tRNA synthetase (DRS), lysyl tRNA synthetase (KRS), asparaginyl tRNA synthetase (PRS), aspartidyl tRNA synthetase (CRS), glutamyl tRNA synthetase (ERS) and prolyl tRNA synthetase (EPRS), which is composed of glutamyl tRNA synthetase (ERS) and prolyl tRNA synthetase (PRS) coupled via a linker containing three WHEP domains. This domain is found on the exterior of the WHEP linker. Following viral infection, serine 990, located in the WHEP linker, is phosphorylated to release EPRS from the MSC, after which the amino-terminal domain of EPRS (1–196 aa), which contains a GST-like domain (1–168 aa) and the linker region L1 (168–196 aa), interacts with poly(rC)-binding protein 2 (PCBP2). Consequently, interferon-β production is increased due to the suppression of PCBP2-mediated ubiquitination and degradation of mitochondrial antiviral-signaling protein (MAVS), ultimately leading to the inhibition of viral replication.\textsuperscript{36} By acquiring additional, differentiated functions with discrete mechanisms that can differ at specific locations, ARSs are key regulators of physiological homeostasis.\textsuperscript{16}

This review focuses on WRS, one of the most extensively studied ARSs. Information regarding its evolution, structural features, and context-dependent biological functions, particularly in immunity, reveals its significant roles in immune regulation and its therapeutic potential.

**Architecture for the catalytic reaction**

Specific recognition by tryptophanyl tRNA synthetase (WRS) of its substrates, Trp and tRNA, is critical for maintaining fidelity in protein synthesis. WRS belongs to the Class Ic ARS family, containing an RF domain with two highly conserved signature sequences, namely, KMSKS (Lys-Met-Ser-Lys-Ser) and HIGH (His-Ile-Gly-His); the former contributes to amino acid activation and the latter stabilizes both ATP during amino acid activation and the 3’ end of the tRNA for amino acid transfer.\textsuperscript{3,37,38} The C-terminal alpha helical domain is the binding site for the tRNA anticodon. While the WRS from *Bacillus stearothermophilus* (bWRS) requires two domains for the catalytic reaction, eukaryotic WRSs, such as those from yeast and archaea, have acquired an extra...
N-terminal domain, referred to as a eukaryote-specific extension (ESE), of 100 amino acid residues. Furthermore, in vertebrates, including humans, WRS has an N-terminal extension of 154 amino acids (N154) that is composed of the ESE and an additional vertebrate-specific extension (VSE), constituting the full-length (FL)-human WRS comprising 471 amino acids. Although the reaction catalyzed by WRS occurs through a similar “induced-fit mechanism” and involves a profound reorganization of the RF domain through conformational changes, human WRS uses a more complex catalytic reaction than bWRS. For example, in the aminoacylation reaction, homo-dimeric WRS exhibits “half-site” activity, meaning that only one monomer of the homo-dimeric WRS operates at a time. A structural analysis of the WRS-tryptophan-ATP complex has revealed that one WRS monomer, in the form of a semi-closed KMSAS loop, binds to tryptophan, whereas the other monomer, in the form of a closed KMSAS loop, binds to both tryptophan and ATP. Recognition of Trp induces a conformational change in the AIDQ motif of human WRS to generate a deep pocket for Trp binding and the activation and coupled movement of the N-terminal extension and C-terminal domain, leading to ATP binding of the KMSAS loop in a closed conformation, thereby securing the position of ATP for catalysis and coupling of the C-terminal tRNA-binding domain for Trp transfer.

Structural metamorphosis for non-catalytic reactions

Undoubtedly, the N-terminal extension domain of human WRS was adopted to undertake non-canonical
functions. The addition of the WHEP domain, WRSs occurred at the chordate stage and have been preserved ever since (Fig. 1). Recently, it has been proposed that a dimeric FL-WRS (Fig. 2c) can crosslink with two toll-like receptor 4-myeloid differentiation factor 2 (MD2) (Fig. 2d) heterodimers via N154, where WHEP (from 8–64), located in the N154 regions, is pivotal. WHEP inserts between the TLR4 and MD2 of one heterodimer, with the terminal domain of the N154 region binding the other TLR4 in trans, leading to TLR4-MD2 dimerization and macrophage activation (Fig. 2e). By contrast, mini-WRS, which lack parts of the WHEP domain, seldom induces functional dimerization.11,20 Rather, mini-WRS, a naturally occurring alternative splice variant of WRS that lacks the N-terminal 47 amino acids, and T1- and T2-WRS, which are proteolytic products of secreted FL-WRS and lack significant parts of the WHEP domain, are composed of 71–471 and 94–471 amino acids, respectively, and have anti-angiogenic effects11,43,44. For example, after proteolytic cleavage, T2-WRS (Fig. 2f) binds VE-cadherin, an endothelial cell adherens junction molecule. VE-cadherin has two conserved tryptophan residues at positions 2 and 4 of the N-terminal extracellular domain (EC)-1, which is a key determinant for the dimerization of VE-cadherin in preformed blood vessels. In newly generated blood vessels, EC1 in the VE-cadherin monomer (Fig. 2g) is exposed owing to endothelial cell budding. Similar to other ARSs, human WRS has developed a tryptophan-binding pocket as a specific active site27,39,43,45,46. After proteolytic cleavage of the N-terminal extension covering the binding pocket, the tryptophan-binding sites are exposed, and the two proteins bind via the tryptophan residues in EC1 (Fig. 2h)47. Therefore, it is reasonable that human FL-WRS, with a completely preserved N-terminal extension, does not exert angiostatic effects48,49. N154 in human WRS has probably evolved to achieve a non-catalytic multi-function while simultaneously contributing to catalytic activity based on the fact that T2-WRS cannot perform aminoaacylation because of the lack of the N-terminal extension domain participating in the reaction, which mini-WRS can perform (Fig. 2b)44.

### WRS signaling and clinical relevance

#### Extracellular signaling of secreted WRS

WRS is secreted into the extracellular space in response to certain stimuli. For example, upon pathogenic infection, but prior to tumor necrosis factor-α (TNF-α) production, WRS is rapidly secreted from monocytes without de novo synthesis, although the mechanism of secretion is not completely known. The secreted FL-WRS, but not mini-WRS, interacts with TLR2 and/or TLR4-MD on macrophages, leading to the activation of innate immune responses, in which TNF-α and chemokine production,
Fig. 2 Various structures of WRS and their interactions with specific receptors.  

a Schematic representation of domains in WRS from prokaryotes (B. stearothermophilus), lower eukaryotes (S. cerevisiae), and higher organisms (H. sapiens). The Rossmann Fold (RF) catalytic domain and anticodon-binding domain (ABD) are well conserved in all WRSs. In the RF domain, the three characteristic types of motif have slightly different sequences among species. The eukaryotic-specific extension (ESE) is common in eukaryotic WRSs. Human full-length (FL)-WRS also has the vertebrate-specific extension (VSE) at the N-terminal appended site. Alternative splicing can produce a mini-WRS where a portion of the VSE is truncated. After being secreted into the extracellular space, the T1 and T2-WRSs are generated by proteolytic cleavage, which removes the ESE, including the entire VSE sequence.  

b The aminoacylation activity of the various forms of WRSs in different species. All the WRSs, with the exception of T2-WRS, are capable of aminoacylation.  

c–h Representative model of the structural arrangement of WRS and their specific interactions with receptors. FL-WRS (c), dimeric human FL-WRS (PDB 1R6T) binding to two TLR4/MD2 heterodimers (PDB 3FXI) through the WHEP domain and the N154 terminus in trans (d, e), T2-WRS (PDB 1O5T) with truncated WHEP entirely cuts off the N-terminus (f), interaction of T2-WRS with the EC1 domain in VE-cadherin (PDB 3PPE). Trp residues present in the EC1 domain bind to the Trp binding pocket present in the RF domain of WRS (g, h).
neutrophil infiltration, and increased phagocytosis are prominent. These responses eliminate invading pathogens in the very early phase of infection, implying that there is a crucial role for FL-WRS as an endogenous ligand of human TLR2/4 in countering infections and immune regulation (Fig. 3a)\(^ {20,50} \). In support of this hypothesis, compared with healthy subjects, high levels of WRS are consistently detected in the serum of critically ill patients with sepsis, a potentially lethal complication of a severe infection. Recent preliminary data have shown that there is a significant positive correlation among WRS levels and sepsis severity, the sepsis-associated organ failure assessment (SOFA) score, and deaths (unpublished data); the data therefore suggest a pivotal role for WRS in sepsis pathophysiology.

By contrast, when endothelial cells are stimulated with IFN-\(\gamma\), an angiostatic cytokine, the expressed WRS forms a tertiary complex with annexin II and S100A10, which regulate exocytosis. A small fraction of the complexed WRS can become dissociated from annexin II and S100A10, and secreted from cells\(^ {51} \). This secretion does not seem to proceed through the classical secretion pathways involving the Golgi, as it is not blocked by treatment with brefeldin A or A23187, inhibitors of ER-Golgi-transport and calcium-dependent exocytosis, respectively\(^ {51,52} \). After secretion, FL-WRS is cleaved by plasmin and/or elastases, which are both critical proteases involved in angiogenesis\(^ {53} \). T2-WRS potently inhibits new angiogenesis, acting via VE-cadherin, a critical player in angiogenesis and vascular permeability at the intracellular junction between endothelial cells\(^ {31,35,39,48,54} \). This T2-WRS/VE-cadherin interaction prevents the activation of VEGFR and subsequent ERK-mediated signaling, which suppress endothelial migration and proliferation (Fig. 3b)\(^ {48,55,56} \).
Intracellular signaling of WRS

Since WRS is a housekeeping enzyme, its overexpression in various cells and tissues under diverse physiological environments is a rather unexpected finding. With respect to development and aging, WRS expression is increased both in the developing salivary grand of *Drosophila* and in aged human epidermis. WRS mRNA levels have been shown to be increased for a specific time during the differentiation of human monocyte-derived macrophage and dendritic cells. Furthermore, WRS is highly expressed not only in cells infected with human cytomegalovirus and hepatitis B virus but also in mouse intestines infected with *Cholera vibrio*. However, the reasons for this WRS overexpression and the underlying mechanisms remain unclear.

Endothelial WRS mRNA expression can also be increased in response to IFN-γ, which is mediated by transcription factor binding to gene promoters, including the gamma-activated sequence and the interferon-sensitive response element in STAT-1 and IFN regulatory factor, respectively. WRS can translocate into the nucleus, using a potential nuclear localization sequence proximal to the C-terminus. In the absence of nuclear WRS, DNA-PKcs (the catalytic subunit of DNA dependent protein kinase) is independently linked to poly [ADP-ribose] polymerase 1 (PARP-1), with Ku70/80 serving as a bridge between the two. Ku70/80 binding to both DNA-PKcs and PARP-1 orients the C-terminal domain of PARP-1 to allow for its phosphorylation by DNA-PKcs. In this state, PARP-1 cannot PARylate DNA-PKcs. However, nuclear WRS can displace Ku70/80 and bind to both DNA-PKcs and PARP-1. The WHEP domain of WRS bridges the C-terminal kinase domain of DNA-PKcs to the N-terminal domain of PARP-1, where WRS enables Trp-AMP, an intermediate amino-adenylate product, to occupy the active site. When Trp-AMP occupies the active site of WRS, the WHEP domain opens and is available for interacting with DNA-PKcs and PARP-1, thus stimulating the PARylation of DNA-PKcs by PARP-1. Finally, the PARylated DNA-PKcs then phosphorylates p53, leading to p53-driven anti-proliferative effects and senescence. These findings imply that the functions of nuclear WRS may concur with those of extracellular WRS as an angiostatic cytokine, consistent with the well-known functional integration of IFN-γ signaling and p53 activation. This furthermore suggests roles for WRS in cell death or cancer (Fig. 3b).

Tryptophan metabolism is closely linked to IFN-γ-mediated immune regulation, which induces a dual effect on its metabolism. Firstly, there is an increase in the rate of degradation of Trp by the indoleamine 2,3-dioxygenase (IDO) pathway, where IDO is strongly increased in macrophages and dendritic cells. The resulting depletion of Trp levels represses immune cell activation and proliferation in the microenvironment. In addition, the products of Trp catabolism (quinolinic acid and 3-hydroxyanthranilic acid) can induce T cell apoptosis, leading to immune tolerance. Secondly, the accumulation of tryptophan into the Trp–tRNA complexes available for protein synthesis provides a protective mechanism for immune cells (Fig. 3b). Treatment of cytotoxic T lymphocyte antigen-4 (CTLA-4), a negative regulator of T cell activation, with human PBMCs induced concomitant increased expression of both IDO and WRS in CD4+ T cells, which prevents CD4+ T cell activation through an IDO-dependent mechanism. Moreover, CD8+ T cells only showed increased WRS expression, not IDO, and were able to maintain their activation status via the Flu antigen, which is unaffected by CTLA-4 pretreatment, rendering WRS a Trp reservoir for protein synthesis.

In addition, given that immune cells possess many tryptophan-rich proteins compared with proteins in general, such as the human major histocompatibility complex antigens, complement factor B, and β-2 microglobulin, which are known to be induced by IFN-γ and immunoglobulins, it is plausible that WRS and Trp cooperate to regulate the activities of various immune cells. Clinically, along with changes in the ratio of serum kynurenine, a metabolite of the IDO pathway, to tryptophan, an imbalance in the expressions of IDO and WRS has been suggested to be associated with autoimmune disorders. Patients with Graves’ disease (GD) show increased kynurenine to Trp ratios and have increased IDO expression in B cells and dendritic cells (DCs), indicating immune suppression; however, GD-derived CD4+ T cells have increased WRS expression and their proliferation was not inhibited by IDO expression in DCs from GD-patients, suggesting the activation of autoreactive T cells. Furthermore, in immune thrombocytopenia, decreased IDO expression and increased WRS expression in CD4+ and CD8+ cells have been proposed to enhance the survival of autoreactive T cells. In rheumatoid arthritis patients, the increased expression of WRS mRNA may be a cause of CD3+ T cell activation (Fig. 3b).

Conclusion and future prospects

Beyond its role in protein synthesis, WRS has evolved to play a role in immune regulation. Following an infection, WRS, in combination with WHEP, is immediately secreted by monocytes, the first responder cells, leading to inflammatory reactions that eliminate invading pathogens. Since FL-WRS serves as an endogenous ligand of human TLR2 and TLR4, it is easy to conclude that this protein plays a significant role as an immune activator in various immune responses, including innate immunity, the development of immune cells, and differentiation, as
well as adaptive immunity. Moreover, WRS has simultaneously acquired anti-inflammatory properties through diverse mechanisms such as alternative splicing and proteolytic cleavage. WRS is the only ARS whose expression is induced by the IFN-γ produced by innate immune cells and T cells under various immunological contexts. WRS also plays a central regulatory role in IFN-γ-induced anti-angiogenesis and cell survival or death. Since inflammation increases protease activity, the hyper-secretion of FL-WRS results in increased levels of T2-WRS, which suppresses the spread of inflammation through its angiostatic activity and the activation of p53 in the nucleus. FL-WRS, containing the WHEP domain, can also induce a pro-apoptotic state. In addition, during Trp metabolism, WRS participates in the activation and/or inhibition of immune cells, including macrophages, dendritic cells, and T cells, by providing tryptophan-binding activity. By placing a device within the N-terminal extension that can perform two different mechanisms, either activating or inhibiting inflammation, WRS serves as a “yin-yang” modulator of inflammation (Fig. 3).

Sepsis is a syndrome with heterogeneous immunopathology, including acute hyper-inflammation and immunosuppression that cannot overcome nosocomial and opportunistic infections. In sepsis patients who have high WRS levels in the early acute phase, excessive WRS-induced inflammation probably occurs, and antagonizing WRS may be a therapeutic strategy for sepsis; by contrast, in immunocompromised septic patients with monocyte dysfunction, injections of FL-WRS or N154 may serve as an appropriate treatment to boost weakened immunity.

Studies on the function of WRS, not only as a p53 modulator but also an angiostatic agent, suggest that WRS could be a therapeutic target for various diseases, including cancer. Current clinical data examining the expression of WRS in cancer tissues indicate that the role of WRS in tumor biology is not simple and seems to be context-dependent. In several cancers, including gastric adenocarcinoma, colorectal and ovarian cancer, high levels of WRS expression are associated with a favorable prognosis, and WRS was recently included as a predictive biomarker for unnecessary adjuvant chemotherapy after surgery for resectable gastric cancer. By contrast, in oral squamous cell carcinoma, high levels of WRS are positively correlated with tumor stage, invasion, and depth, and it has been suggested that secreted WRS may induce cancer cell migration. Therefore, how altered WRS expression levels differentially affect the fate of cancer cells and how secreted WRS regulates the cancer microenvironment that contains various cells, including immune cells, are interesting questions. In order for WRS to be meaningful as a prognostic marker, or even as a therapeutic target, further in-depth research needs to be conducted. Until now, in patients with autoimmune diseases, the purpose of WRS overexpression in immune cells has been assumed to be as a Trp repository; however, this notion arises because only certain phenomena have been examined. Therefore, it is very important to examine the mechanisms underlying immune cell proliferation/activation and metabolism in detail.

Acknowledgements
I sincerely thank Profs. S. Kim, J. Shin, and J.J. Choi, and Y.T. Kim for their valuable comments and support in preparing this review. This study was supported by the Global Frontier Project Grants (NRF2015M3A6A4065732) of Ministry of Science and ICT through the National Research Foundation, Republic of Korea.

Conflict of interest
The author declares that he has no conflict of interest.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 31 March 2018 Revised: 15 August 2018 Accepted: 27 August 2018. Published online: 7 January 2019

References
1. Xu, Z. J. et al. Tryptophanyl-tRNA synthetase from Bacillus subtilis. Characterization and role of hydrophobicity in substrate recognition. J. Biol. Chem. 264, 4304–4311 (1989).
2. Yang, X. L. et al. Functional and crystal structure analysis of active site adaptations of a potent anti-angiogenic human tRNA synthetase. Structure 15, 793–805 (2007).
3. Suga, H., Hayashi, G. & Terasaka, N. The RNA origin of transfer RNA aminoaacylation and beyond. Philos. Trans. R. Soc. Lond. B Biol. Sci. 366, 2959–2964 (2011).
4. Pang, Y. L., Poruri, K. & Martinis, S. A. tRNA synthetase: tRNA aminoaacylation and beyond. Wiley Interdiscip. Rev. RNA 5, 461–480 (2014).
5. Paley, E. L. Chaperon-like activation of serum-inducible tryptophanyl-tRNA synthetase phosphorylation through refolding as a tool for analysis of clinical samples. Transl. Oncol. 4, 377–389 (2011).
6. Williams, T. L., Yin, Y. W. & Carter, C. W. Jr. Selective inhibition of bacterial tryptophanyl-tRNA synthetases by indolmycin is mechanism-based. J. Biol. Chem. 291, 253–265 (2016).
7. Fang, P. & Guo, M. Evolutionary limitation and opportunities for developing tRNA synthetase inhibitors with S-binding-mode classification. Life (Basel) 5, 1703–1725 (2015).
8. Erains, G., Det PIE, M., Poch, O., Gangloff, J. & Moras, D. Partition of tRNA synthetases into two classes based on mutually exclusive sets of sequence motifs. Nature 347, 203–206 (1990).
9. Ribas de Pouplana, L. & Schimmel, P. Aminoacyl-tRNA synthetases: potential markers of genetic code development. Trends Biochem. Sci. 26, 591–596 (2001).
10. Ribas de Pouplana, L. & Schimmel, P. Two classes of tRNA synthetases suggested by sterically compatible dockings on tRNA acceptor stem. Cell 104, 191–193 (2001).
11. Guo, M., Yang, X. L. & Schimmel, P. New functions of aminoaacyl-tRNA synthetases beyond translation. Nat. Rev. Mol. Cell Biol. 11, 668–674 (2010).
12. Lee, S. W., Cho, B. H., Park, S. G. & Kim, S. Aminoacyl-tRNA synthetase complexes: beyond translation. J. Cell Sci. 117, 3725–3734 (2004).
13. Rho, S. B. et al. A multifunctional repeated motif is present in human bifunctional tRNA synthetase. J. Biol. Chem. 273, 11267–11273 (1998).
14. Kao, J. et al. Endothelial monocyte-activating polypeptide. I. A novel tumor-derived polypeptide that activates host-response mechanisms. J. Biol. Chem. 267, 20239–20247 (1992).
15. Koonin, E. V. et al. Eukaryotic translation elongation factor 1 gamma contains a glutathione transferase domain—study of a diverse, ancient protein
superfamily using motif search and structural modeling. Protein Sci. 3, 2045–2054 (1994).

16. Xu, X. et al. Unique domain appended to vertebrate tRNA synthetase is essential for vascular development. Nat. Commun. 3, 681 (2012).

17. Guo, M., Schimmel, P. & Yang, X. L. Functional expansion of human tRNA synthetases achieved by structural inventions. FEBS Lett. 584, 434–442 (2010).

18. Smirnova, E. V., Lakunina, V. A., Tarassov, I., Krasheninnikov, I. A. & Kamenski, P. A. Noncanonical functions of aminoacyl-tRNA synthetases. Biochemistry (Mosc.) 77, 15–25 (2012).

19. Wei, Z. et al. Alternative splicing creates two new architectures for human tyrosyl-tRNA synthetase: activation of ATP by induced-fit. J. Mol. Biol. 362, 1159–1180 (2006).

20. Ilyin, V. A. et al. A crystal structure of ligand-free tyrosyl-tRNA synthetase: domain movements fragment the adenine nucleotide binding site. Protein Sci. 9, 218–231 (2000).

21. Xu, X. et al. An alternative conformation of human TrpRS suggests a role of zinc in activating non-enzymatic function. RNA Biol. 15, 649–668 (2018).

22. Otani, A. et al. A fragment of human TrpRS as a potent antagonist of ocular angiogenesis. Proc. Natl. Acad. Sci. USA 99, 178–183 (2002).

23. Yang, X. L., Schimmel, P. & Ervasti, K. L. Relationship of two human tRNA synthetases achieved in cell signaling. Trends Biochem. Sci. 29, 250–256 (2004).

24. Ghanipour, A. et al. The prognostic significance of tryptophanyl-tRNA synthetase in colorectal cancer. Cancer Epidemiol. Biomark. Prev. 18, 2949–2956 (2009).

25. Zhou, Q. et al. Orthogonal use of a human tRNA synthetase active site to achieve multifunctionality. Nat. Struct. Mol. Biol. 17, 57–61 (2010).

26. Taima, E. & Schimmel, P. Inhibition of tumor angiogenesis by a natural fragment of a tRNA synthetase: new insights into drug design. Saccharomyces cerevisiae tryptophanyl-tRNA synthetase: new insights into different enzymatic states. Nucleic Acids Res. 34, 2045–2054 (2006).

27. Scand. J. Clin. Lab. Invest. 68, 161–170 (2008).

28. Seshiah, P. & Andrew, D. J. WRS-85D: a tryptophanyl-tRNA synthetase–lipopolysaccharide complex using motif search and structural modeling. Trends Glycosci. Glycotechnol. 29, 107–112 (2017).

29. Park, M. C. et al. Secreted human glycy-tRNA synthetase implicated in defense against ERK-activated tumorigenesis. Proc. Natl. Acad. Sci. USA 106, E640–E647 (2009).

30. Kise, Y. et al. A short peptide insertion crucial for angiostatic activity of human mini tryptophanyl-tRNA synthetase: domain movements fragment the adenine nucleotide binding site. Proc. Natl. Acad. Sci. USA 109, 14470–14475 (2012).

31. Nakamoto, T., Miyakoshi, M., Tanaka, T. & Wakisaka, K. Identification of a residue crucial for the angiostatic activity of human mini tryptophanyl-tRNA synthetase by focusing on its molecular evolution. Sci. Rep. 6, 24750 (2016).

32. Ramirez, B. L. et al. Brugia malayi asparaginyl-transfer RNA synthetase induces antiviral immunity. Nat. Commun. 5, 3798 (2014).

33. Tzima, E. et al. Biologically active fragment of a human tRNA synthetase achieved by structural inventions. J. Mol. Biol. 285, 183–195 (1999).

34. Park, S. J., Ahn, H. S., Kim, J. S. & Lee, C. Evaluation of multi-tRNA synthetase complex by multiple reaction monitoring mass spectrometry coupled with size exclusion chromatography. PLoS ONE 10, e0142253 (2015).

35. Cho, H. Y. et al. Assembly of multi-tRNA synthetase complex via heterotetrameric glutathione transferase-homology domains. J. Biol. Chem. 290, 29313–29328 (2015).

36. Sajoth, W. et al. Trp-tRNA synthetase bridges DNA-PKcs to PARP-1 to link ING-gamma and p53 signaling. Nat. Chem. Biol. 8, 547–554 (2012).

37. Guo, M. & Schimmel, P. Essential non translational functions of tRNA synthetases. Nat. Chem. Biol. 9, 145–153 (2013).

38. Nakagawa, K. Human tryptophanyl-tRNA synthetase binds with heme to enhance its aminoaacylation activity Biochemistry 46, 11291–11298 (2007).

39. Kisselev, L., Frolova, L. & Haenni, A. L. Interferon inducibility of mammalian tryptophanyl-tRNA synthetase: new perspectives. Trends Biochem. Sci. 18, 263–267 (1993).

40. Kise, Y. et al. A short peptide insertion crucial for angiostatic activity of human tyrosyl-tRNA synthetase: new insights into different enzymatic states. Nat. Struct. Mol. Biol. 11, 149–156 (2004).

41. Ramirez, B. L. et al. Brugia malayi asparaginyl-transfer RNA synthetase induces chemotaxis of human leukocytes and activates G-protein-coupled receptors OR51R1 and OR51R2. J. Infect. Dis. 193, 1164–1171 (2006).

42. Kwon, M. A., Wang, C., Vodanovic-Ivanjko, S., Howard, O. M. & Kuhn, L. A. Interleukin-8-like activity in a filarial asparaginyl-tRNA synthetase. Mol. Biochem. Parasitol. 185, 66–69 (2012).

43. Wakuagui, K. et al. Induction of angiogenesis by a fragment of human tyrosyl-tRNA synthetase. J. Biol. Chem. 277, 20124–20126 (2002).

44. Taiz, E. et al. VE-cadherin links tRNA synthetase cytosome to anti-angiogenic function. J. Biol. Chem. 280, 2405–2408 (2005).

45. Lee, E. Y. et al. Infusion-specific phosphorilation of glutaryl-prolyl RNA synthetase induces antiviral immunity. Nat. Immunol. 17, 1252–1262 (2016).

46. Shen, N. et al. Catalytic mechanism of the tryptophan activation reaction revealed by crystal structures of human tryptophanyl-tRNA synthetase in different enzymatic states. Nucleic Acids Res. 36, 1288–1299 (2008).

47. Zhou, M., Dong, X., Shen, N., Zhen, G. & Ding, C. Crystal structures of Saccharomyces cerevisiae tryptophanyl-tRNA synthetase: new insights into the mechanism of tryptophan activation and implications for anti-fungal drug design. Nucleic Acids Res. 38, 3399–3413 (2010).

48. Wakuagui, K. et al. A human aminoacyl-tRNA synthetase as a regulator of angiogenesis. Proc. Natl. Acad. Sci. USA 99, 173–177 (2002).

49. Shen, N., Guo, L., Yang, B., Jin, Y. & Ding, C. Structure of human tryptophanyl-tRNA synthetase in complex with tRNATrp reveals the molecular basis of tRNA recognition and specificity. Nucleic Acids Res. 34, 3246–3258 (2006).
88. Negrutskii, B. S., Shalak, V. F., Kerjan, P., Efskaya, A. V. & Mirande, M. Functional interaction of mammalian valyl-tRNA synthetase with elongation factor EF-1alpha in the complex with EF-1H. J. Biol. Chem. 274, 4545–4550 (1999).
89. Bec, G., Kerjan, P. & Waller, J. P. Reconstitution in vitro of the valyl-tRNA synthetase-elongation factor (EF) 1 beta gamma delta complex. Essential roles of the NH2-terminal extension of valyl-tRNA synthetase and of the EF-1 delta subunit in complex formation. J. Biol. Chem. 269, 2086–2092 (1994).
90. Quevillon, S. & Mirande, M. The p18 component of the multisynthetase complex shares a protein motif with the beta and gamma subunits of eukaryotic elongation factor 1. FEBS Lett. 395, 63–67 (1996).
91. Kim, J. E. et al. An elongation factor-associating domain is inserted into human cysteinyl-tRNA synthetase by alternative splicing. Nucleic Acids Res. 28, 2866–2872 (2000).
92. Yang, X. L. et al. Gain-of-function mutational activation of human tRNA synthetase procytokine. Chem. Biol. 14, 1323–1333 (2007).
93. Zheng, Y. G., Wei, H., Ling, C., Xu, M. G. & Wang, E. D. Two forms of human cytoplasmic arginyl-tRNA synthetase produced from two translation initiation by a single mRna. Biochemistry 45, 1338–1344 (2006).
94. Francon, M., Kaminska, M., Kerjan, P. & Mirande, M. The N-terminal domain of mammalian Lysyl-tRNA synthetase is a functional tRNA-binding domain. J. Biol. Chem. 277, 1762–1769 (2002).
95. Francon, M. & Mirande, M. Functional dissection of the eukaryotic-specific tRNA-interacting factor of lysyl-tRNA synthetase. J. Biol. Chem. 278, 1472–1479 (2003).
96. Ryckelynck, M., Gege, R. & Frugier, M. Yeast tRNA(Asp) charging accuracy is threatened by the N-terminal extension of aspartyl-tRNA synthetase. J. Biol. Chem. 278, 9683–9690 (2003).
97. Reed, V. S., Wastney, M. E. & Yang, D. C. Mechanisms of the transfer of aminocacyl-tRNA from aminocacyl-tRNA synthetase to the elongation factor 1 alpha. J. Biol. Chem. 269, 32993–32996 (1994).
98. Jia, J., Artt, A., Ray, P. S. & Fox, P. L. WHED domains direct noncanonical function of glutamyl-Prolyl tRNA synthetase in translational control of gene expression. Mol. Cell 29, 679–690 (2008).
99. Howard, O. M. et al. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J. Exp. Med. 196, 781–791 (2002).
100. Ko, Y. G., Kang, Y. S., Kim, E. K., Park, S. G. & Kim, S. Nucleolar localization of human methionyl-tRNA synthetase and its role in ribosomal RNA synthesis. J. Cell Biol. 149, 567–574 (2000).
101. Chang, C. Y., Chien, C. I., Chang, C. P., Lin, B. C. & Wang, C. C. A WHEP domain regulates the dynamic structure and activity of Caenorhabditis elegans glycyl-tRNA synthetase: J. Biol. Chem. 291, 16567–16575 (2016).
102. Wakahagi, K. & Schimmel, P. Two distinct cytokines released from a human aminocacyl-tRNA synthetase. Science 284, 147–151 (1999).